Sugi Predict

Sugi Predict / Compounds / SCHEMBL6476899

SCHEMBL6476899

SCHEMBL6476899

O=S(=O)(c1ccccn1)C(F)(F)F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.46
▸ PKM P14618 2/20 0.46
▸ NFE2L2 Q16236 3/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ SLC40A1 Q9NP59 4/20 0.42
▸ OXTR P30559 1/20 0.40
▸ ABCC9 O60706 1/20 0.40
▸ ABCC8 Q09428 1/20 0.40
▸ KCNJ11 Q14654 1/20 0.40
▸ KCNJ8 Q15842 1/20 0.40
▸ MAOA P21397 1/20 0.39
▸ MAOB P27338 1/20 0.39
▸ LOX P28300 1/20 0.39
▸ GLO1 Q04760 1/20 0.39
▸ KAT6A Q92794 1/20 0.39
▸ KEAP1 Q14145 1/20 0.37
▸ CYP2C9 P11712 1/20 0.36
▸ CNR2 P34972 1/20 0.36
▸ POLB P06746 2/20 0.36
▸ MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30528257 1.00 KDM4E (0.46) KDM4EPKMNFE2L2L3MBTL1SLC40A1
SCHEMBL25377920 0.84 PKM (0.43) KDM4EPKMNFE2L2L3MBTL1SLC40A1
SCHEMBL25376162 0.84 NFE2L2 (0.45) KDM4EPKMNFE2L2L3MBTL1SLC40A1
SCHEMBL25376274 0.81 KDM4E (0.41) KDM4EPKMNFE2L2L3MBTL1SLC40A1
SCHEMBL25377058 0.81 CA1 (0.48) KDM4EPKMNFE2L2L3MBTL1SLC40A1
SCHEMBL11485425 0.81 PKM (0.41) KDM4EPKMNFE2L2L3MBTL1SLC40A1
SCHEMBL6904752 0.81 KDM4E (0.47) KDM4EPKMNFE2L2L3MBTL1SLC40A1
SCHEMBL542032 0.81 KDM4E (0.47) KDM4EPKMNFE2L2L3MBTL1SLC40A1
SCHEMBL25376922 0.80 KDM4E (0.40) KDM4EPKMNFE2L2L3MBTL1SLC40A1
SCHEMBL25376957 0.80 L3MBTL1 (0.41) KDM4EPKMNFE2L2L3MBTL1SLC40A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114956926-B Method for rapidly converting carboxylic acid compounds into amide and/or ester 中国科学院兰州化学物理研究所 2023-08-11 — — CN claimed
CN-114933511-B Method for quickly converting carboxyl into aldehyde group 中国科学院兰州化学物理研究所 2023-02-24 — — CN claimed
CN-114956926-A Method for quickly converting carboxylic acid compounds into amides and/or esters 中国科学院兰州化学物理研究所 2022-08-30 — — CN claimed
CN-114933511-A Method for quickly converting carboxyl into aldehyde group 中国科学院兰州化学物理研究所 2022-08-23 — — CN claimed
CN-120004783-A Synthesis method of trifluoromethyl heteroarene 中国科学院大学 2025-05-16 — — CN disclosed
CN-114956926-B Method for rapidly converting carboxylic acid compounds into amide and/or ester 中国科学院兰州化学物理研究所 2023-08-11 — — CN disclosed
CN-114933511-B Method for quickly converting carboxyl into aldehyde group 中国科学院兰州化学物理研究所 2023-02-24 — — CN disclosed
CN-114933511-B Method for quickly converting carboxyl into aldehyde group 中国科学院兰州化学物理研究所 2023-02-24 — — CN disclosed
CN-114956926-A Method for quickly converting carboxylic acid compounds into amides and/or esters 中国科学院兰州化学物理研究所 2022-08-30 — — CN disclosed
CN-114956926-A Method for quickly converting carboxylic acid compounds into amides and/or esters 中国科学院兰州化学物理研究所 2022-08-30 — — CN disclosed
CN-114933511-A Method for quickly converting carboxyl into aldehyde group 中国科学院兰州化学物理研究所 2022-08-23 — — CN disclosed
CN-114933511-A Method for quickly converting carboxyl into aldehyde group 中国科学院兰州化学物理研究所 2022-08-23 — — CN disclosed
US-10189813-B2 Formylated N-heterocyclic derivatives as FGFR4 inhibitors NOVARTIS AG (CH) 2019-01-29 — — US disclosed
US-20180065951-A1 Formylated N-heterocyclic derivatives as FGFR4 inhibitors NOVARTIS PHARMA AG (CH) 2018-03-08 — — US disclosed
EP-3274344-A1 FORMYLATED N-HETEROCYCLIC DERIVATIVES AS FGFR4 INHIBITORS NOVARTIS AG (CH) 2018-01-31 — — EP disclosed
WO-2017173604-A1 PYRROLE DERIVATIVES HUA MEDICINE (SHANGHAI) LTD. (CN) 2017-10-12 — — WO disclosed
WO-2016151499-A1 FORMYLATED N-HETEROCYCLIC DERIVATIVES AS FGFR4 INHIBITORS NOVARTIS AG (CH) 2016-09-29 — — WO disclosed
US-6933322-B2 Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus WYETH (US) 2005-08-23 — — US disclosed
US-20030216442-A1 Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus WYETH 2003-11-20 — — US disclosed
US-20030203941-A1 Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus WYETH (US) 2003-10-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203941-A1 Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus GPR119, INSR, SLC5A1 KDM4E 493/4885PKM 703/4885NFE2L2 1287/4885
US-20180065951-A1 Formylated N-heterocyclic derivatives as FGFR4 inhibitors FGFR4, FGFR1, FGFR3 KDM4E 320/4885PKM 2730/4885NFE2L2 2948/4885
US-20030216442-A1 Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus INSR, GPR119, SLC5A1 KDM4E 1358/4885PKM 1826/4885NFE2L2 596/4885
US-10189813-B2 Formylated N-heterocyclic derivatives as FGFR4 inhibitors FGFR4, FGFR1, FGFR3 KDM4E 320/4885PKM 2730/4885NFE2L2 2948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.